Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
AL amyloidosis presents a diagnostic challenge due to its varied symptoms, but advancements in therapeutic options, including CyBorD plus daratumumab and emerging antifibril monoclonal antibodies, offer hope for better patient management.
Cardiology July 9th 2024
Cleveland Clinic Journal of Medicine
Cardiac amyloidosis often presents with nonspecific symptoms and requires a high index of suspicion and specialized diagnostic protocols to ensure accurate diagnosis and effective management.
Cardiology May 16th 2024
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH